Global Inherited Cancer Genome Testing Market Size, Status and Forecast 2022-2028

TABLE OF CONTENTS

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Inherited Cancer Genome Testing Market Size Growth Rate by Type (2022-2028)
  • 1.2.2 Breast Cancer
  • 1.2.3 Lung Cancer
  • 1.2.4 Blood Cancer
  • 1.2.5 Liver Cancer
  • 1.2.6 Stomach Cancer
  • 1.2.7 Others
• 1.3 Market by Application
  • 1.3.1 Global Inherited Cancer Genome Testing Market Share by Application (2022-2028)
  • 1.3.2 General Hospitals
  • 1.3.3 Specialty Clinics
• 1.4 Study Objectives
• 1.5 Years Considered

2 Executive Summary

• 2.1 Global Inherited Cancer Genome Testing Market Size
• 2.2 Inherited Cancer Genome Testing Market Size by Regions
  • 2.2.1 Inherited Cancer Genome Testing Growth Rate by Regions (2022-2028)
  • 2.2.2 Inherited Cancer Genome Testing Market Share by Regions (2022-2028)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Use Cases

3 Key Players

• 3.1 Inherited Cancer Genome Testing Revenue by Players (2022 & 2028)
• 3.2 Inherited Cancer Genome Testing Key Players Headquarters and Area Served
• 3.3 Key Players Inherited Cancer Genome Testing Product/Solution/Service
• 3.4 Date of Enter into Inherited Cancer Genome Testing Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown by Type and by Application

• 4.1 Global Inherited Cancer Genome Testing Market Size by Type (2022-2028)
• 4.2 Global Inherited Cancer Genome Testing Market Size by Application (2022-2028)

5 North America

• 5.1 North America Inherited Cancer Genome Testing Market Forecast (2022-2028)
• 5.2 Inherited Cancer Genome Testing Key Players in North America
• 5.3 North America Inherited Cancer Genome Testing Market Size by Type
• 5.4 North America Inherited Cancer Genome Testing Market Size by Application

6 Europe

• 6.1 Europe Inherited Cancer Genome Testing Market Forecast (2022-2028)
• 6.2 Inherited Cancer Genome Testing Key Players in Europe
• 6.3 Europe Inherited Cancer Genome Testing Market Size by Type
• 6.4 Europe Inherited Cancer Genome Testing Market Size by Application

7 Asia-Pacific

• 7.1 Asia-Pacific Inherited Cancer Genome Testing Market Forecast (2022-2028)
• 7.2 Inherited Cancer Genome Testing Key Players in Asia-Pacific
• 7.3 Asia-Pacific Inherited Cancer Genome Testing Market Size by Type
• 7.4 Asia-Pacific Inherited Cancer Genome Testing Market Size by Application

8 Rest of World

• 8.1 Latin America
  • 8.1.1 Latin America Inherited Cancer Genome Testing Market Analysis
  • 8.1.2 Key Players in Latin America
• 8.2 Middle East & Africa
  • 8.2.1 Middle East & Africa Inherited Cancer Genome Testing Market Analysis
  • 8.2.2 Key Players in Middle East & Africa

9 International Player Profiles

• 9.1 23andMe
  • 9.1.1 23andMe Company Details
  • 9.1.2 23andMe Description and Business Overview
  • 9.1.3 23andMe Inherited Cancer Genome Testing Introduction
  • 9.1.4 23andMe Revenue in Inherited Cancer Genome Testing Business (2022 & 2028)
  • 9.1.5 23andMe Recent Development
• 9.2 Agilent Technologies
  • 9.2.1 Agilent Technologies Company Details
  • 9.2.2 Agilent Technologies Description and Business Overview
  • 9.2.3 Agilent Technologies Inherited Cancer Genome Testing Introduction
  • 9.2.4 Agilent Technologies Revenue in Inherited Cancer Genome Testing Business (2022 & 2028)
  • 9.2.5 Agilent Technologies Recent Development
• 9.3 Bio-Rad Laboratories
  • 9.3.1 Bio-Rad Laboratories Company Details
  • 9.3.2 Bio-Rad Laboratories Description and Business Overview
  • 9.3.3 Bio-Rad Laboratories Inherited Cancer Genome Testing Introduction
  • 9.3.4 Bio-Rad Laboratories Revenue in Inherited Cancer Genome Testing Business (2022 & 2028)
  • 9.3.5 Bio-Rad Laboratories Recent Development
• 9.4 Centogene
  • 9.4.1 Centogene Company Details
  • 9.4.2 Centogene Description and Business Overview
  • 9.4.3 Centogene Inherited Cancer Genome Testing Introduction
  • 9.4.4 Centogene Revenue in Inherited Cancer Genome Testing Business (2022 & 2028)
  • 9.4.5 Centogene Recent Development
• 9.5 Color Genomics
  • 9.5.1 Color Genomics Company Details
  • 9.5.2 Color Genomics Description and Business Overview
  • 9.5.3 Color Genomics Inherited Cancer Genome Testing Introduction
  • 9.5.4 Color Genomics Revenue in Inherited Cancer Genome Testing Business (2022 & 2028)
  • 9.5.5 Color Genomics Recent Development
• 9.6 Gene By Gene
  • 9.6.1 Gene By Gene Company Details
  • 9.6.2 Gene By Gene Description and Business Overview
  • 9.6.3 Gene By Gene Inherited Cancer Genome Testing Introduction
  • 9.6.4 Gene By Gene Revenue in Inherited Cancer Genome Testing Business (2022 & 2028)
  • 9.6.5 Gene By Gene Recent Development
• 9.7 Illumina
  • 9.7.1 Illumina Company Details
  • 9.7.2 Illumina Description and Business Overview
  • 9.7.3 Illumina Inherited Cancer Genome Testing Introduction
  • 9.7.4 Illumina Revenue in Inherited Cancer Genome Testing Business (2022 & 2028)
  • 9.7.5 Illumina Recent Development
• 9.8 LabCorp
  • 9.8.1 LabCorp Company Details
  • 9.8.2 LabCorp Description and Business Overview
  • 9.8.3 LabCorp Inherited Cancer Genome Testing Introduction
  • 9.8.4 LabCorp Revenue in Inherited Cancer Genome Testing Business (2022 & 2028)
  • 9.8.5 LabCorp Recent Development
• 9.9 Myriad Genetics
  • 9.9.1 Myriad Genetics Company Details
  • 9.9.2 Myriad Genetics Description and Business Overview
  • 9.9.3 Myriad Genetics Inherited Cancer Genome Testing Introduction
  • 9.9.4 Myriad Genetics Revenue in Inherited Cancer Genome Testing Business (2022 & 2028)
  • 9.9.5 Myriad Genetics Recent Development
• 9.10 Positive Bioscience
  • 9.10.1 Positive Bioscience Company Details
  • 9.10.2 Positive Bioscience Description and Business Overview
  • 9.10.3 Positive Bioscience Inherited Cancer Genome Testing Introduction
  • 9.10.4 Positive Bioscience Revenue in Inherited Cancer Genome Testing Business (2022 & 2028)
  • 9.10.5 Positive Bioscience Recent Development
• 9.11 Quest Diagnostics
  • 9.11.1 Quest Diagnostics Company Details
  • 9.11.2 Quest Diagnostics Description and Business Overview
  • 9.11.3 Quest Diagnostics Inherited Cancer Genome Testing Introduction
  • 9.11.4 Quest Diagnostics Revenue in Inherited Cancer Genome Testing Business (2022 & 2028)
  • 9.11.5 Quest Diagnostics Recent Development
• 9.12 Thermo Fisher Scientific
  • 9.12.1 Thermo Fisher Scientific Company Details
  • 9.12.2 Thermo Fisher Scientific Description and Business Overview
  • 9.12.3 Thermo Fisher Scientific Inherited Cancer Genome Testing Introduction
  • 9.12.4 Thermo Fisher Scientific Revenue in Inherited Cancer Genome Testing Business (2022 & 2028)
  • 9.12.5 Thermo Fisher Scientific Recent Development

10 Market Dynamics

• 10.1 Industry Trends
• 10.2 Market Drives
• 10.3 Market Challenges
• 10.4 Market Restraints

11 Key Findings in This Report

12 Appendix

• 12.1 Research Methodology
  • 12.1.1 Methodology/Research Approach
  • 12.1.2 Data Source
• 12.2 Disclaimer
• 12.3 Author Details

List of Tables

• Table 1. Global Inherited Cancer Genome Testing Market Size Growth Rate by Type (2022-2028) (US$ Million)
• Table 2. Key Players of Breast Cancer
• Table 3. Key Players of Lung Cancer
• Table 4. Key Players of Blood Cancer
• Table 5. Key Players of Liver Cancer
• Table 6. Key Players of Stomach Cancer
• Table 7. Key Players of Others
• Table 8. Global Inherited Cancer Genome Testing Market Size Growth by Application (2022-2028) (US$ Million)
• Table 9. Global Inherited Cancer Genome Testing Market Size by Regions (2022-2028) (US$ Million)
• Table 10. Global Inherited Cancer Genome Testing Market Share by Regions (2022-2028)
• Table 11. Market Top Trends
• Table 12. Market Use Cases
• Table 13. Global Inherited Cancer Genome Testing Revenue by Players (2022 & 2028) (US$ Million)
• Table 14. Global Inherited Cancer Genome Testing Market Share by Players (2022 &2028)
• Table 15. Key Players Headquarters and Area Served
• Table 16. Key Players Inherited Cancer Genome Testing Product/Solution/Service
• Table 17. Date of Enter into Inherited Cancer Genome Testing Market
• Table 18. Mergers & Acquisitions, Expansion Plans
• Table 19. Global Inherited Cancer Genome Testing Market Size by Type (2022-2028) (US$ Million)
• Table 20. Global Inherited Cancer Genome Testing Market Size Share by Type (2022-2028)
• Table 21. Global Inherited Cancer Genome Testing Market Size by Application (2022-2028) (US$ Million)
• Table 22. Global Inherited Cancer Genome Testing Market Size Share by Application (2022-2028)
• Table 23. North America Key Players Inherited Cancer Genome Testing Revenue (2022 & 2028) & (US$ Million)
• Table 24. North America Key Players Inherited Cancer Genome Testing Market Share (2022 & 2028)
• Table 25. North America Inherited Cancer Genome Testing Market Size by Type (2022-2028) (US$ Million)
• Table 26. North America Inherited Cancer Genome Testing Market Share by Type (2022-2028)
• Table 27. North America Inherited Cancer Genome Testing Market Size by Application (2022-2028) (US$ Million)
• Table 28. North America Inherited Cancer Genome Testing Market Share by Application (2022-2028)
• Table 29. Europe Key Players Inherited Cancer Genome Testing Revenue (2022 & 2028) & (US$ Million)
• Table 30. Europe Key Players Inherited Cancer Genome Testing Market Share (2022 & 2028)
• Table 31. Europe Inherited Cancer Genome Testing Market Size by Type (2022-2028) (US$ Million)
• Table 32. Europe Inherited Cancer Genome Testing Market Share by Type (2022-2028)
• Table 33. Europe Inherited Cancer Genome Testing Market Size by Application (2022-2028) (US$ Million)
• Table 34. Europe Inherited Cancer Genome Testing Market Share by Application (2022-2028)
• Table 35. Asia-Pacific Key Players Inherited Cancer Genome Testing Revenue (2022 & 2028) & (US$ Million)
• Table 36. Asia-Pacific Key Players Inherited Cancer Genome Testing Market Share (2022 & 2028)
• Table 37. Asia-Pacific Inherited Cancer Genome Testing Market Size by Type (2022-2028) (US$ Million)
• Table 38. Asia-Pacific Inherited Cancer Genome Testing Market Share by Type (2022-2028)
• Table 39. Asia-Pacific Inherited Cancer Genome Testing Market Size by Application (2022-2028) (US$ Million)
• Table 40. Asia-Pacific Inherited Cancer Genome Testing Market Share by Application (2022-2028)
• Table 41. Key Players in Latin America
• Table 42. Key Players in Middle East & Africa
• Table 43. 23andMe Company Details
• Table 44. 23andMe Description and Business Overview
• Table 45. 23andMe Inherited Cancer Genome Testing Product
• Table 46. 23andMe Revenue in Inherited Cancer Genome Testing Business 2022 & 2028
• Table 47. 23andMe Recent Development
• Table 48. Agilent Technologies Company Details
• Table 49. Agilent Technologies Description and Business Overview
• Table 50. Agilent Technologies Inherited Cancer Genome Testing Product
• Table 51. Agilent Technologies Revenue in Inherited Cancer Genome Testing Business 2022 & 2028
• Table 52. Agilent Technologies Recent Development
• Table 53. Bio-Rad Laboratories Company Details
• Table 54. Bio-Rad Laboratories Description and Business Overview
• Table 55. Bio-Rad Laboratories Inherited Cancer Genome Testing Product
• Table 56. Bio-Rad Laboratories Revenue in Inherited Cancer Genome Testing Business 2022 & 2028
• Table 57. Bio-Rad Laboratories Recent Development
• Table 58. Centogene Company Details
• Table 59. Centogene Description and Business Overview
• Table 60. Centogene Inherited Cancer Genome Testing Product
• Table 61. Centogene Revenue in Inherited Cancer Genome Testing Business 2022 & 2028
• Table 62. Centogene Recent Development
• Table 63. Color Genomics Company Details
• Table 64. Color Genomics Description and Business Overview
• Table 65. Color Genomics Inherited Cancer Genome Testing Product
• Table 66. Color Genomics Revenue in Inherited Cancer Genome Testing Business 2022 & 2028
• Table 67. Color Genomics Recent Development
• Table 68. Gene By Gene Company Details
• Table 69. Gene By Gene Description and Business Overview
• Table 70. Gene By Gene Inherited Cancer Genome Testing Product
• Table 71. Gene By Gene Revenue in Inherited Cancer Genome Testing Business 2022 & 2028
• Table 72. Gene By Gene Recent Development
• Table 73. Illumina Company Details
• Table 74. Illumina Description and Business Overview
• Table 75. Illumina Inherited Cancer Genome Testing Product
• Table 76. Illumina Revenue in Inherited Cancer Genome Testing Business 2022 & 2028
• Table 77. Illumina Recent Development
• Table 78. LabCorp Company Details
• Table 79. LabCorp Description and Business Overview
• Table 80. LabCorp Inherited Cancer Genome Testing Product
• Table 81. LabCorp Revenue in Inherited Cancer Genome Testing Business 2022 & 2028
• Table 82. LabCorp Recent Development
• Table 83. Myriad Genetics Company Details
• Table 84. Myriad Genetics Description and Business Overview
• Table 85. Myriad Genetics Inherited Cancer Genome Testing Product
• Table 86. Myriad Genetics Revenue in Inherited Cancer Genome Testing Business 2022 & 2028
• Table 87. Myriad Genetics Recent Development
• Table 88. Positive Bioscience Company Details
• Table 89. Positive Bioscience Description and Business Overview
• Table 90. Positive Bioscience Inherited Cancer Genome Testing Product
• Table 91. Positive Bioscience Revenue in Inherited Cancer Genome Testing Business 2022 & 2028
• Table 92. Positive Bioscience Recent Development
• Table 93. Quest Diagnostics Company Details
• Table 94. Quest Diagnostics Description and Business Overview
• Table 95. Quest Diagnostics Inherited Cancer Genome Testing Product
• Table 96. Quest Diagnostics Revenue in Inherited Cancer Genome Testing Business 2022 & 2028
• Table 97. Quest Diagnostics Recent Development
• Table 98. Thermo Fisher Scientific Company Details
• Table 99. Thermo Fisher Scientific Description and Business Overview
• Table 100. Thermo Fisher Scientific Inherited Cancer Genome Testing Product
• Table 101. Thermo Fisher Scientific Revenue in Inherited Cancer Genome Testing Business 2022 & 2028
• Table 102. Thermo Fisher Scientific Recent Development
• Table 103. Inherited Cancer Genome Testing Market Trends
• Table 104. Inherited Cancer Genome Testing Market Drivers
• Table 105. Inherited Cancer Genome Testing Market Challenges
• Table 106. Inherited Cancer Genome Testing Market Restraints
• Table 107. Research Programs/Design for This Report
• Table 108. Key Data Information from Secondary Sources
• Table 109. Key Data Information from Primary Sources

List of Figures

• Figure 1. Global Inherited Cancer Genome Testing Market Share by Type in 2022 & 2028
• Figure 2. Breast Cancer Features
• Figure 3. Lung Cancer Features
• Figure 4. Blood Cancer Features
• Figure 5. Liver Cancer Features
• Figure 6. Stomach Cancer Features
• Figure 7. Others Features
• Figure 8. Global Inherited Cancer Genome Testing Market Share by Application in 2022 & 2028
• Figure 9. General Hospitals Case Studies
• Figure 10. Specialty Clinics Case Studies
• Figure 11. Inherited Cancer Genome Testing Report Years Considered
• Figure 12. Global Inherited Cancer Genome Testing Market Size and Growth Rate (2022-2028) (US$ Million)
• Figure 13. Global Inherited Cancer Genome Testing Market Share by Regions (2022-2028)
• Figure 14. Global Inherited Cancer Genome Testing Market Share by Players in 2021
• Figure 15. Global Inherited Cancer Genome Testing Market Size Market Share by Type (2022-2028)
• Figure 16. Global Inherited Cancer Genome Testing Market Size Market Share by Application (2022-2028)
• Figure 17. Global Inherited Cancer Genome Testing Revenue Market Share by Application in 2021
• Figure 18. North America Inherited Cancer Genome Testing Market Size 2022-2028 (US$ Million)
• Figure 19. Europe Inherited Cancer Genome Testing Market Size 2022-2028 (US$ Million)
• Figure 20. Asia-Pacific Inherited Cancer Genome Testing Market Size 2022-2028 (US$ Million)
• Figure 21. Inherited Cancer Genome Testing Market Size in Latin America (2022-2028) (US$ Million)
• Figure 22. Inherited Cancer Genome Testing Market Size in Middle East & Africa (2022-2028) (US$ Million)
• Figure 23. Bottom-up and Top-down Approaches for This Report
• Figure 24. Data Triangulation
• Figure 25. Key Executives Interviewed